Blood Cancer Talks

In this episode, we review the hottest updates in lymphoma from the American Society of Hematology 2023 meeting with Dr Toby Eyre, a consultant haematologist at the University of Oxford in the UK.
 
Here are the abstracts that were discussed:
 
Mantle Cell Lymphoma
 
1. BOVen trial-A Multicenter Phase 2 Trial of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients with Treatment-Naïve, TP53-Mutant Mantle Cell Lymphoma
 
https://ash.confex.com/ash/2023/webprogram/Paper180069.html
 
2. SYMPATICO Trial: Ibrutinib Combined with Venetoclax in Patients with Relapsed/Refractory Mantle Cell Lymphoma (Late Breaking Abstract)
 
 https://ash.confex.com/ash/2023/webprogram/Paper191921.html
 
Chronic Lymphocytic Leukemia
 
1. FLAIR trial: Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease
 
Link for simultaneous NEJM publication: https://www.nejm.org/doi/10.1056/NEJMoa2310063
 
2. Ibrutinib retreatment in Phase 2 CAPTIVATE study:
 
https://ash.confex.com/ash/2023/webprogram/Paper187128.html
 
Hodgkin Lymphoma
 
1. S1826 outcomes in older adults: 
 
https://ash.confex.com/ash/2023/webprogram/Paper180114.html
 
Diffuse Large B-cell Lymphoma
 
1. Smart STOP study: Lenalidomide, Tafasitamab, Rituximab, and Acalabrutinib Alone and with Combination Chemotherapy for the Treatment of Newly Diagnosed Diffuse Large B-Cell Lymphoma
 
https://ash.confex.com/ash/2023/webprogram/Paper180381.html
 
2. Mosunetuzumab and Polatuzumab Vedotin Demonstrates Preliminary Efficacy in Elderly Unfit/Frail Patients with Previously Untreated Diffuse Large B-Cell Lymphoma
 
https://ash.confex.com/ash/2023/webprogram/Paper177588.html

What is Blood Cancer Talks?

This is a podcast on latest advances in the understanding and management of blood cancers. Here, we will bring a wide range of experts within hematologic malignancies to discuss various topics in depth.
Host: Raj Chakraborty, MD from Columbia University, New York, Ashwin Kishtagari, MD, from Vanderbilt University, Nashville, and Edward Cliff, MD, from Harvard University, Boston
Tweet your suggestions and feedback to @rajshekharucms @AshKishtagari @Eddie_Cliff @BloodCancerTalk